VWR Corporation (NASDAQ:VWR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “VWR’s second-quarter earnings report was quite impressive, with both the top and the bottom line beating the Zacks Consensus Estimate. Geographically, the company recorded growth in Americas during the reported quarter driven by strong sales of equipment and instrumentation. Management is also looking forward to the long-term synergy benefits from the proposed merger with Avantor. The merger is expected to strengthen VWR’s business across the Americas and Europe. While we await the merger to close in the fourth quarter of 2017 we note that the stock price has already reached close to Avantor’s offer price and hence the short-term upside potential of VWR is limited now. On the flip side, a drop in EMEA-APAC sales was disappointing. Moreover, foreign currency was a major dampener. VWR’s poor margin scenario also raises concern.”

VWR has been the subject of a number of other research reports. BidaskClub raised VWR Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. ValuEngine raised VWR Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $31.67.

VWR Corporation (VWR) traded down 0.075% during trading on Thursday, hitting $33.125. The stock had a trading volume of 127,154 shares. VWR Corporation has a 1-year low of $24.42 and a 1-year high of $37.25. The firm’s 50 day moving average is $33.02 and its 200 day moving average is $31.30. The firm has a market cap of $4.37 billion, a price-to-earnings ratio of 30.671 and a beta of 1.19.

VWR Corporation (NASDAQ:VWR) last released its quarterly earnings data on Monday, July 31st. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The firm had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.16 billion. VWR Corporation had a return on equity of 15.54% and a net margin of 3.12%. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.42 earnings per share. On average, analysts anticipate that VWR Corporation will post $1.87 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “VWR Corporation (VWR) Downgraded by Zacks Investment Research” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/14/vwr-corporation-vwr-downgraded-by-zacks-investment-research.html.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of VWR Corporation by 4,641.8% in the 1st quarter. BlackRock Inc. now owns 4,072,333 shares of the medical research company’s stock worth $114,840,000 after acquiring an additional 3,986,452 shares in the last quarter. Shapiro Capital Management LLC acquired a new position in shares of VWR Corporation in the 1st quarter worth approximately $66,793,000. JPMorgan Chase & Co. boosted its holdings in shares of VWR Corporation by 79.2% in the 1st quarter. JPMorgan Chase & Co. now owns 4,531,105 shares of the medical research company’s stock worth $127,777,000 after acquiring an additional 2,002,306 shares in the last quarter. Earnest Partners LLC boosted its holdings in shares of VWR Corporation by 116.8% in the 1st quarter. Earnest Partners LLC now owns 1,797,102 shares of the medical research company’s stock worth $50,678,000 after acquiring an additional 968,313 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its holdings in shares of VWR Corporation by 39.4% in the 1st quarter. Macquarie Group Ltd. now owns 1,933,570 shares of the medical research company’s stock worth $54,527,000 after acquiring an additional 546,246 shares in the last quarter.

VWR Corporation Company Profile

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.

Get a free copy of the Zacks research report on VWR Corporation (VWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.